Climb Bio Investor Relations Material
Latest events
M&A Announcement
Climb Bio
Q1 2025
14 May, 2025
Q4 2024
25 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Climb Bio Inc
Access all reports
Eliem Therapeutics, Inc. is a biotechnology company focused on developing therapies for neuronal excitability disorders, which are associated with conditions like chronic pain, epilepsy, depression, and anxiety. The company’s approach involves advancing clinical-stage compounds that target neurological diseases, aiming to address significant unmet medical needs. Eliem Therapeutics is headquartered in Wilmington, Delaware, and its shares are listed on the NASDAQ.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
CLYM
Country
🇺🇸 United States